{"schema_version":"secwatch.filing_event.v1","accession":"0000805928-25-000010","form_type":"8-K","ticker":"AXGN","cik":"0000805928","company_name":"Axogen, Inc.","filed_at":"2025-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.391995+00:00","generated_at":"2026-05-26T05:17:14.778321+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Axogen Q4 2024 revenue up 15.1% to $49.4M; reports first quarterly net income of $0.4M","bullets":["Q4 revenue $49.4M (+15.1% YoY); gross margin 76.1% vs 74.6%.","Q4 net income $0.4M ($0.01 EPS) vs net loss $3.9M prior year; adjusted net income $3.5M ($0.07 EPS).","Full-year 2024 revenue $187.3M (+17.8% YoY); adjusted EBITDA $19.8M vs -$1.1M in 2023.","FDA accepted BLA for Avance Nerve Graft; PDUFA goal date Sept 5, 2025; anticipates approval.","2025 guidance: revenue growth 15-17%, gross margin 73-75%, expects positive net cash flow."],"urls":{"canonical":"https://secwatch.observer/filing/0000805928-25-000010","json":"https://secwatch.observer/filing/0000805928-25-000010.json","markdown":"https://secwatch.observer/filing/0000805928-25-000010.md","text":"https://secwatch.observer/filing/0000805928-25-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/805928/000080592825000010/0000805928-25-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/805928/000080592825000010/axgn-20250225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T05:17:14.778321+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}